Trending

metabolic diseases

MiNA’s gene-activating tech wins an AstraZeneca alliance

MiNA’s gene-activating tech wins an AstraZeneca alliance

UK biotech MiNA Therapeutics’ RNA-based gene-activating technology has caught the eye of big pharma AstraZeneca. AZ has teamed

X

MiNA’s gene-activating tech wins an AstraZeneca alliance

https://pharmaphorum.com/news/minas-gene-activating-tech-wins-an-astrazeneca-alliance/

Novo’s new oral GLP-1 Rybelsus still has obstacles to overcome

Novo’s new oral GLP-1 Rybelsus still has obstacles to overcome

The FDA approval last Friday of Novo Nordisk’s Rybelsus as the first orally-active GLP-1 agonist is only the

X

Novo’s new oral GLP-1 Rybelsus still has obstacles to overcome

https://pharmaphorum.com/news/novos-new-oral-glp-1-still-has-obstacles-to-overcome/

Vertex looks beyond cystic fibrosis with $950m Semma buy

Vertex looks beyond cystic fibrosis with $950m Semma buy

Vertex Pharma is all-but synonymous with cystic fibrosis (CF) treatment but wants to diversify into new areas, including

X

Vertex looks beyond cystic fibrosis with $950m Semma buy

https://pharmaphorum.com/news/vertex-looks-beyond-cystic-fibrosis-with-950m-semma-buy/

Pfizer, Novo invest in Swedish patient stratification startup

Pfizer, Novo invest in Swedish patient stratification startup

Funds will go towards development of AMRA’s body composition profiling tool AMRA Profiler.

X

Pfizer, Novo invest in Swedish patient stratification startup

https://pharmaphorum.com/news/pfizer-novo-invest-swedish-patient-stratification-startup/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com